EE Times
What makes a quantum company valuable? Owen Lozman in EE Times ahead of Cannes

Ahead of the World Quantum Cannes Festival on 17–18 November, EE Times asked two quantum investors what makes a quantum company valuable. Pat Brans spoke with Owen Lozman, Managing Partner of 55 North, and Nardo Manaloto, Managing Partner of Qubits Ventures, about technical bottlenecks, commercial timing and customer adoption.
Timing, not invention
Owen’s starting point comes from semiconductor investing. “Generally in deep tech, we’re not looking for, ‘Does the invention work?’ but, ‘Does it solve a problem at the time at which it’s going to be needed by the customer?’” he told EE Times.
In quantum, that often means helping system builders move from laboratory assemblies to reliable, reproducible equipment. Owen cited our portfolio company Monarch Quantum as an example. Optical modules that can be manufactured consistently become more important as quantum companies professionalise their supply chains.
Three kinds of quantum company
Owen separates the market into three types of business, each with its own commercial challenges and measures of progress.
Component suppliers must deliver reliable, reproducible equipment as quantum computer builders scale production. Revenue growth, production cost and profitability can be measured early. Owen favours technologies that serve several qubit architectures and several potential customers.
Quantum computer developers must move from demonstrating individual qubits to building useful, scalable systems. The questions are technical differentiation and whether they must build manufacturing capacity themselves or can use existing semiconductor infrastructure.
Software and applications companies must understand customer problems and be ready when suitable hardware arrives. Evidence that customers will pay matters, and so does timing: expanding before the hardware is ready can leave a company burning cash without enough revenue.
Value before revenue
“In a lot of deep tech, the revenue is rarely the exit trigger,” Owen said. “Technology is often the exit trigger.” A system developer may lack a capability that a smaller company has built, and bringing the two together can create more value than either holds alone. Some companies pursuing complete quantum systems may end up merging or becoming component suppliers, while their technology remains important.
For applications companies, the risk is being early. “If you’re a year or two early and you’re burning too much cash, it’s very, very difficult to sustain your company,” he said. “Survivability will be a key kind of KPI for a lot of the assets in this space.”
Who captures the value of a sensor
Quantum sensing raises a different question. The company selling an instrument can sit far from the organisation that gains most from it. “It’s hard making money out of a sensor,” Owen said. “It’s hard to get people to recover the value if the buyer and the beneficiary are not close in the value chain.” The business model has to tie the price to an outcome the customer recognises and will pay for.
In pharmaceutical research, Owen sees openings in instruments that simplify drug discovery, improve toxicology assessment or support better clinical-trial endpoints. Qualification is slow, because customers protect processes that already work. The same caution helps once a product is established: “Once you’re in, it’s very hard to get displaced.”
See you in Cannes
Owen sits on the festival’s Honorary Committee and is among the investors supervising its closed-door Investor Day, as he told The Recursive. The World Quantum Cannes Festival brings technology providers, investors and potential customers together at the Palais des Festivals et des Congrès. For investors, it is a chance to hear how prospective users define their problems and what they would pay to solve them.
Read the full article in EE Times.